Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder
Go back to Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder| (NASDAQ: CMND) | Delayed: 2.36 +0.06 (2.61%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.30 | 52 Week High | $ | |||
| Open | $2.28 | 52 Week Low | $ | |||
| Day High | $2.42 | P/E | N/A | |||
| Day Low | $2.28 | EPS | $ | |||
| Volume | 66,623 | |||||
